Metropolitan Life Insurance Co. NY maintained its stake in Meridian Bioscience Inc. (NASDAQ:VIVO) during the first quarter, Holdings Channel reports. The institutional investor owned 32,820 shares of the company’s stock at the end of the first quarter. Metropolitan Life Insurance Co. NY’s holdings in Meridian Bioscience were worth $453,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in VIVO. Louisiana State Employees Retirement System raised its stake in Meridian Bioscience by 1.8% in the first quarter. Louisiana State Employees Retirement System now owns 17,200 shares of the company’s stock worth $237,000 after buying an additional 300 shares in the last quarter. Arizona State Retirement System raised its stake in Meridian Bioscience by 1.4% in the first quarter. Arizona State Retirement System now owns 21,941 shares of the company’s stock worth $303,000 after buying an additional 300 shares in the last quarter. RiverPoint Capital Management LLC raised its stake in Meridian Bioscience by 2.9% in the first quarter. RiverPoint Capital Management LLC now owns 20,965 shares of the company’s stock worth $289,000 after buying an additional 599 shares in the last quarter. Mason Street Advisors LLC raised its stake in Meridian Bioscience by 7.2% in the first quarter. Mason Street Advisors LLC now owns 9,868 shares of the company’s stock worth $136,000 after buying an additional 667 shares in the last quarter. Finally, Thrivent Financial For Lutherans raised its stake in Meridian Bioscience by 3.9% in the first quarter. Thrivent Financial For Lutherans now owns 23,640 shares of the company’s stock worth $326,000 after buying an additional 890 shares in the last quarter. 86.50% of the stock is currently owned by institutional investors.

Meridian Bioscience Inc. (NASDAQ:VIVO) traded down 0.179% during midday trading on Tuesday, hitting $13.925. The stock had a trading volume of 20,936 shares. Meridian Bioscience Inc. has a 52 week low of $10.75 and a 52 week high of $19.85. The company’s 50 day moving average price is $14.79 and its 200-day moving average price is $13.99. The stock has a market capitalization of $587.68 million, a price-to-earnings ratio of 27.850 and a beta of 0.89.

Meridian Bioscience (NASDAQ:VIVO) last announced its earnings results on Thursday, July 27th. The company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. Meridian Bioscience had a return on equity of 16.93% and a net margin of 10.77%. The company had revenue of $50.14 million for the quarter, compared to analyst estimates of $49.13 million. During the same quarter in the prior year, the company earned $0.21 EPS. The firm’s revenue for the quarter was down 1.0% compared to the same quarter last year. Equities analysts anticipate that Meridian Bioscience Inc. will post $0.67 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 17th. Investors of record on Monday, August 7th will be given a dividend of $0.125 per share. The ex-dividend date is Thursday, August 3rd. This represents a $0.50 annualized dividend and a dividend yield of 3.58%. Meridian Bioscience’s payout ratio is 98.04%.

WARNING: “Meridian Bioscience Inc. (VIVO) Position Maintained by Metropolitan Life Insurance Co. NY” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/meridian-bioscience-inc-vivo-position-maintained-by-metropolitan-life-insurance-co-ny/1490352.html.

A number of research firms have recently commented on VIVO. Zacks Investment Research lowered Meridian Bioscience from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. BidaskClub lowered Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Thursday, July 6th. Finally, Canaccord Genuity raised their price target on Meridian Bioscience from $13.00 to $15.00 and gave the stock a “hold” rating in a research report on Wednesday, May 3rd. Three equities research analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $14.75.

About Meridian Bioscience

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience Inc. (NASDAQ:VIVO).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.